Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report report published on Friday. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Mizuho dropped their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $2.18.

Adaptimmune Therapeutics Trading Up 3.9 %

Shares of NASDAQ ADAP opened at $0.29 on Friday. Adaptimmune Therapeutics has a 1-year low of $0.26 and a 1-year high of $1.65. The stock has a market capitalization of $74.41 million, a P/E ratio of -1.32 and a beta of 2.52. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The business has a fifty day moving average price of $0.54 and a 200 day moving average price of $0.69.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Long Focus Capital Management LLC grew its position in shares of Adaptimmune Therapeutics by 54.1% during the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock worth $11,040,000 after buying an additional 7,194,503 shares in the last quarter. Two Seas Capital LP acquired a new stake in shares of Adaptimmune Therapeutics in the 4th quarter valued at $7,992,000. Renaissance Technologies LLC lifted its position in shares of Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock worth $1,361,000 after purchasing an additional 869,949 shares during the last quarter. Rock Springs Capital Management LP grew its stake in shares of Adaptimmune Therapeutics by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock worth $1,338,000 after purchasing an additional 58,000 shares in the last quarter. Finally, FMR LLC increased its holdings in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after buying an additional 50,419 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.